Table 1

Clinical and biologic characteristics of patients stratified by lymphoid neogenesis

Demographic

All (n = 46)

LN+ (n = 20)

LN- (n = 26)

P

Age (years)

50 (37; 61)

48 (36; 59)

54 (38.5; 63)

NS

Male (%)

26 (57)

13 (65)

13 (50)

NS

Disease duration (years)

7.5 (3.75; 13)

6 (2; 14)

8 (4.5; 12.5)

NS

Follow-up (months)

27 (9; 52)

21 (8; 50)

27 (12; 55)

NS

Clinical status

TJC

1 (1; 2)

1 (1; 2)

1 (1; 2)

NS

SJC

1 (1; 2)

1 (1; 2)

1 (1; 2)

NS

Articular pattern, n (%)

Oligoarthritis

23 (50)

13 (57)

10 (43)

NS

Poliarthritis

18 (39)

7 (39)

11 (61)

Mixed (peripheral plus axial)

5 (11)

2 (40)

3 (60)

ESR (mm/h)

19 (10; 30)

20 (9; 31)

18 (12; 25)

NS

CRP (mg/dl)

0.72 (0.32; 2.01)

1.00 (0.51; 1.83)

0.44 (0.29; 2.32)

NS

DAS28

3.31 (3.01; 4.2)

3.31 (2.94; 4.14)

3.34 (3.01; 4.28)

NS

Erosive disease, n (%)

12 (26)

7 (35)

5 (19)

NS

Treatment

DMARDs taken, n (%)

23 (50)

12 (60)

11 (42)

NS

TNF-blockers, n (%)

8 (17)

1 (5)

7 (27)

0.041

EULAR response

Treated (n = 28)

LN+ (n = 11)

LN- (n = 17)

P

No response, n (%)

8 (29)

3 (27)

5 (29)

0.541

Moderate, n (%)

7 (25)

4 (36)

3 (18)

Good, n (%)

13 (46)

4 (36)

9 (53)

Data are expressed as median (IQR) or as percentage.

Celis et al. Arthritis Research & Therapy 2012 14:R93   doi:10.1186/ar3817